Q2 EPS Forecast for Moleculin Biotech Decreased by Analyst

Moleculin Biotech, Inc. (NASDAQ:MBRX) – HC Wainwright lowered their Q2 2026 earnings estimates for Moleculin Biotech in a note issued to investors on Friday, May 15th. HC Wainwright analyst S. Nik now forecasts that the company will earn ($1.65) per share for the quarter, down from their prior estimate of ($1.40). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($4.89) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($4.60) EPS.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($3.54) EPS for the quarter, missing analysts’ consensus estimates of ($2.33) by ($1.21).

Other analysts have also issued reports about the stock. Wall Street Zen lowered shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $22.00.

Moleculin Biotech Trading Down 0.9%

NASDAQ MBRX opened at $2.09 on Tuesday. The company’s 50-day moving average price is $2.33 and its 200-day moving average price is $4.60. The stock has a market cap of $11.16 million, a PE ratio of -0.06 and a beta of 1.74. Moleculin Biotech has a 12 month low of $1.79 and a 12 month high of $25.00.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.